Levocetirizine dihydrochloride orally-dissolving film - NAL Pharma

Drug Profile

Levocetirizine dihydrochloride orally-dissolving film - NAL Pharma

Alternative Names: NAL 6013

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NAL Pharma
  • Class Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Hypersensitivity

Most Recent Events

  • 07 Sep 2016 Chemical structure information added
  • 16 Aug 2016 Levocetirizine dihydrochloride orally-dissolving film - NAL Pharma is available for licensing as of 16 Aug 2016. http://www.nalpharma.com/licensing.php?id=7&lang=en
  • 16 Aug 2016 Clinical trials in Hypersensitivity (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top